Souhaitez-vous accéder aux communiqués récents ?

New York City, NY, Dec. 04, 2025 (GLOBE NEWSWIRE) -- In 2026, there is absolutely no need to use illegal anabolic steroids to build serious muscle growth, size, strength, and a lean, defined...

Bestyrelsesformand Jukka Pertola genopstiller ikke ved Tryg A/S kommende generalforsamling i marts 2026. Næstformand Steffen Kragh indstilles som ny formand for bestyrelsen og bestyrelsesmedlem...

Chair of the Supervisory Board, Jukka Pertola, will not seek reelection at the coming Annual General Meeting of Tryg A/S in March 2026. Deputy Chair, Steffen Kragh, is nominated as new Chair of the...

New York, USA, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to...

WASHINGTON DC, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Most Popular Legal Steroids for Muscle Building from CrazyBulk: Best-Selling Steroid Alternatives for Lean Muscle Growth and Cutting in 2026 ...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings...

LOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Industry Analysis: The AquaSculpt ice hack method combining cold water thermogenesis with plant-based metabolic support supplementation has emerged...

– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. ...

ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on...

Agios today announced topline results from the 52-week double-blind period of the global RISE UP Phase 3 trial